Literature DB >> 30401935

Benefit in patients with PD-L1-positive TNBC.

Diana Romero1.   

Abstract

Entities:  

Year:  2019        PMID： 30401935     DOI： 10.1038/s41571-018-0127-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.

Authors:  Sylvia Adams; Jennifer R Diamond; Erika Hamilton; Paula R Pohlmann; Sara M Tolaney; Ching-Wei Chang; Wei Zhang; Koho Iizuka; Paul G Foster; Luciana Molinero; Roel Funke; John Powderly
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

2.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245
  2 in total
  7 in total

1.  A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.

Authors:  Mozhan Haji Ghaffari; Miganoosh Simonian; Ali Salimi; Ebrahim Mirzadegan; Niloufar Sadeghi; Mohammad-Reza Nejadmoghaddam; Nasim Ebrahimnezhad; Ghazaleh Fazli; Ramina Fatemi; Ali-Ahmad Bayat; Mohammadali Mazloomi; Hodjattallah Rabbani
Journal:  Breast Cancer       Date:  2022-08-18       Impact factor: 3.307

2.  Molecular determinants of drug response in TNBC cell lines.

Authors:  Nathan M Merrill; Eric J Lachacz; Nathalie M Vandecan; Peter J Ulintz; Liwei Bao; John P Lloyd; Joel A Yates; Aki Morikawa; Sofia D Merajver; Matthew B Soellner
Journal:  Breast Cancer Res Treat       Date:  2019-10-26       Impact factor: 4.872

Review 3.  Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.

Authors:  Wenjie Zhao; Jinhua Liu; Yaqun Li; Zichao Chen; Dongmei Qi; Zhen Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

4.  Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.

Authors:  Yingnan Si; Ya Zhang; Jia-Shiung Guan; Hanh Giai Ngo; Angela Totoro; Ajeet Pal Singh; Kai Chen; Yuanxin Xu; Eddy S Yang; Lufang Zhou; Runhua Liu; Xiaoguang Margaret Liu
Journal:  Vaccines (Basel)       Date:  2021-08-10

Review 5.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

6.  The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database.

Authors:  Yongfeng Li; Meng Chen; Barbara Pardini; Mihnea P Dragomir; Anthony Lucci; George A Calin
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

7.  Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers.

Authors:  Yingnan Si; Kai Chen; Hanh Giai Ngo; Jia Shiung Guan; Angela Totoro; Zhuoxin Zhou; Seulhee Kim; Taehyun Kim; Lufang Zhou; Xiaoguang Liu
Journal:  Pharmaceutics       Date:  2022-01-07       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.